{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:17:26Z","timestamp":1783113446154,"version":"3.54.6"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,4,30]],"date-time":"2027-04-30T00:00:00Z","timestamp":1809043200000},"content-version":"am","delay-in-days":241,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K23DA062822"],"award-info":[{"award-number":["K23DA062822"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["K76AG074878"],"award-info":[{"award-number":["K76AG074878"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007921","name":"University of Pittsburgh","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Institute on Drug Abuse Clinical Trials Network","doi-asserted-by":"publisher","award":["3UG1DA049436-03S1"],"award-info":[{"award-number":["3UG1DA049436-03S1"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.josat.2026.209986","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:45:13Z","timestamp":1777610713000},"page":"209986","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Trends and geographic disparities in maintenance dose of buprenorphine for opioid use disorder: A cross-sectional pharmacy claims analysis"],"prefix":"10.1016","volume":"188","author":[{"given":"Roisin M.","family":"Sabol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget M.","family":"Mayrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryant","family":"Shuey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payel","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie J.","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.josat.2026.209986_bb0005","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1080\/00952990.2021.1903023","article-title":"Common themes in early state policy responses to substance use disorder treatment during COVID-19","volume":"47","author":"Andraka-Christou","year":"2021","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"issue":"5","key":"10.1016\/j.josat.2026.209986_bb0010","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1377\/hlthaff.2022.01513","article-title":"Buprenorphine treatment for opioid use disorder: Comparison of insurance restrictions, 2017-21","volume":"42","author":"Andraka-Christou","year":"2023","journal-title":"Health Affairs (Project Hope)"},{"issue":"1","key":"10.1016\/j.josat.2026.209986_bb0015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/jrh.12569","article-title":"Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder","volume":"38","author":"Andrilla","year":"2022","journal-title":"The Journal of Rural Health"},{"issue":"4","key":"10.1016\/j.josat.2026.209986_bb0020","doi-asserted-by":"crossref","DOI":"10.1111\/jrh.70078","article-title":"Differences in the travel burden for care between rural and urban patients with opioid use disorder by insurance type","volume":"41","author":"Andrilla","year":"2025","journal-title":"The Journal of Rural Health"},{"issue":"5","key":"10.1016\/j.josat.2026.209986_bb0025","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/add.14522","article-title":"What should clinicians do as fentanyl replaces heroin?","volume":"114","author":"Bisaga","year":"2019","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.josat.2026.209986_bb0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.3099","article-title":"Medicare beneficiary receipt of methadone by drive time to opioid treatment programs","volume":"8","author":"Cantor","year":"2025","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2026.209986_bb0035","author":"CDC"},{"key":"10.1016\/j.josat.2026.209986_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.josat.2023.209186","article-title":"Development and validation of a community-level social determinants of health index for drug overdose deaths in the HEALing Communities Study","volume":"157","author":"Cesare","year":"2024","journal-title":"Journal of Substance Use and Addiction Treatment"},{"issue":"9","key":"10.1016\/j.josat.2026.209986_bb0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.34540","article-title":"Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl","volume":"6","author":"Chambers","year":"2023","journal-title":"JAMA Network Open"},{"issue":"7","key":"10.1016\/j.josat.2026.209986_bb0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.23708","article-title":"Changes in buprenorphine and methadone supplies in the US during the COVID-19 pandemic","volume":"5","author":"Chen","year":"2022","journal-title":"JAMA Network Open"},{"issue":"2","key":"10.1016\/j.josat.2026.209986_bb0055","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/ADM.0000000000000635","article-title":"Executive summary of the focused update of the ASAM national practice guideline for the treatment of opioid use disorder","volume":"14","author":"Crotty","year":"2020","journal-title":"Journal of Addiction Medicine"},{"issue":"9","key":"10.1016\/j.josat.2026.209986_bb0060","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1377\/hlthaff.2025.00343","article-title":"States with substantial increases in buprenorphine uptake did so with increased Medicaid prescribing, 2018-24","volume":"44","author":"Crystal","year":"2025","journal-title":"Health Affairs"},{"key":"10.1016\/j.josat.2026.209986_bb0065","series-title":"Modifications to labeling of buprenorphine-containing transmucosal products for the treatment of opioid dependence","author":"Department of Health and Human Services & Food and Drug Administration","year":"2024"},{"issue":"1","key":"10.1016\/j.josat.2026.209986_bb0070","first-page":"293","article-title":"Crosswalking ZIP codes to census geographies: Geoprocessing the U.S. Department of Housing & Urban Developments ZIP code crosswalk files","volume":"22","author":"Din","year":"2020","journal-title":"Cityscape"},{"issue":"3","key":"10.1016\/j.josat.2026.209986_bb0075","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/ADM.0000000000001287","article-title":"Racial and ethnic disparities in geographic availability of buprenorphine","volume":"18","author":"Drake","year":"2024","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2026.209986_bb0080","author":"Economic Research Service"},{"key":"10.1016\/j.josat.2026.209986_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.110991","article-title":"The association between community social vulnerability and prescription opioid availability with individual opioid overdose","volume":"252","author":"El Ibrahimi","year":"2023","journal-title":"Drug and Alcohol Dependence"},{"issue":"8","key":"10.1016\/j.josat.2026.209986_bb0090","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"147","author":"Elm","year":"2007","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1016\/j.josat.2026.209986_bb0095","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/10550887.2011.642758","article-title":"Effect of buprenorphine dose on treatment outcome","volume":"31","author":"Fareed","year":"2012","journal-title":"Journal of Addictive Diseases"},{"issue":"4","key":"10.1016\/j.josat.2026.209986_bb0100","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jamapsychiatry.2022.0004","article-title":"Evaluation of increases in drug overdose mortality rates in the US by race and ethnicity before and during the COVID-19 pandemic","volume":"79","author":"Friedman","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.josat.2026.209986_bb0105","series-title":"Drug overdose deaths in the United States, 2003-2023","author":"Garnett","year":"2024"},{"key":"10.1016\/j.josat.2026.209986_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.dadr.2023.100193","article-title":"Differences in medicaid expansion effects on buprenorphine treatment utilization by county rurality and income: A pharmacy data claims analysis from 2009\u20132018","volume":"9","author":"Golan","year":"2023","journal-title":"Drug and Alcohol Dependence Reports"},{"issue":"11","key":"10.1016\/j.josat.2026.209986_bb0115","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","article-title":"Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers","volume":"28","author":"Greenwald","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.josat.2026.209986_bb0120","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/1475-6773.12093","article-title":"Adoption and diffusion of evidence-based addiction medications in substance abuse treatment","volume":"49","author":"Heinrich","year":"2014","journal-title":"Health Services Research"},{"issue":"1","key":"10.1016\/j.josat.2026.209986_bb0125","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"issue":"11","key":"10.1016\/j.josat.2026.209986_bb0130","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1377\/hlthaff.2025.00191","article-title":"State laws banning prior authorization for medications for opioid use disorder increased substantially, 2015-23","volume":"44","author":"Hu","year":"2025","journal-title":"Health Affairs"},{"key":"10.1016\/j.josat.2026.209986_bb0135","series-title":"HUD USPS ZIP code crosswalk files","author":"HUD Office of Policy Development and Research","year":"2022"},{"issue":"9","key":"10.1016\/j.josat.2026.209986_bb0140","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1007\/s11606-023-08165-9","article-title":"Long-term prospects for telemedicine in opioid use disorder (OUD) treatment: Results from a longitudinal survey of OUD clinicians","volume":"38","author":"Huskamp","year":"2023","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.josat.2026.209986_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2025.104748","article-title":"Retention and dropout from sublingual and extended-release buprenorphine treatment: A comparative analysis of data from a nationally representative sample of commercially-insured people with opioid use disorder in the United States","volume":"138","author":"Ivasiy","year":"2025","journal-title":"The International Journal on Drug Policy"},{"issue":"4","key":"10.1016\/j.josat.2026.209986_bb0150","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.7028","article-title":"Assessment of community-level vulnerability and access to medications for opioid use disorder","volume":"5","author":"Joudrey","year":"2022","journal-title":"JAMA Network Open"},{"issue":"2S Suppl 1","key":"10.1016\/j.josat.2026.209986_bb0155","first-page":"1","article-title":"The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update","volume":"14","year":"2020","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2026.209986_bb0160","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm7129e2","article-title":"Vital signs: Drug overdose deaths, by selected sociodemographic and social determinants of health characteristics \u2014 25 states and the District of Columbia, 2019\u20132020","volume":"71","author":"Kariisa","year":"2022","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"issue":"6","key":"10.1016\/j.josat.2026.209986_bb0165","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.18493","article-title":"Receipt of buprenorphine and naltrexone for opioid use disorder by race and ethnicity and insurance type","volume":"8","author":"Khatri","year":"2025","journal-title":"JAMA Network Open"},{"issue":"7","key":"10.1016\/j.josat.2026.209986_bb0170","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.18389","article-title":"Duration of methadone and buprenorphine-naloxone treatment","volume":"8","author":"Kleinman","year":"2025","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.josat.2026.209986_bb0175","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/08897077.2022.2060424","article-title":"Sociodemographic differences in quality of treatment to medicaid enrollees receiving buprenorphine","volume":"43","author":"Landis","year":"2022","journal-title":"Substance Abuse"},{"issue":"3","key":"10.1016\/j.josat.2026.209986_bb0180","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Annals of Internal Medicine"},{"issue":"10","key":"10.1016\/j.josat.2026.209986_bb0185","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1176\/appi.ajp.21111141","article-title":"Impact of COVID-19 telehealth policy changes on buprenorphine treatment for opioid use disorder","volume":"179","author":"Lin","year":"2022","journal-title":"The American Journal of Psychiatry"},{"issue":"9","key":"10.1016\/j.josat.2026.209986_bb0190","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1377\/hlthaff.2025.00207","article-title":"The quality of opioid use disorder treatment in medicare is low and lags behind Medicaid","volume":"44","author":"Mark","year":"2025","journal-title":"Health Affairs (Project Hope)"},{"issue":"2","key":"10.1016\/j.josat.2026.209986_bb0195","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2014","author":"Mattick","year":"2014","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.josat.2026.209986_bb0200","author":"Medications for Opioid Use Disorder: For Healthcare and Addiction Professionals, Policymakers, Patients, and Families: Updated 2021"},{"key":"10.1016\/j.josat.2026.209986_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2025.104805","article-title":"Barriers to accessing medications for opioid use disorder among rural individuals","volume":"140","author":"Morenz","year":"2025","journal-title":"The International Journal on Drug Policy"},{"issue":"12","key":"10.1016\/j.josat.2026.209986_bb0210","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1258\/jrsm.2011.110180","article-title":"The answer is 17 years, what is the question: Understanding time lags in translational research","volume":"104","author":"Morris","year":"2011","journal-title":"Journal of the Royal Society of Medicine"},{"issue":"6","key":"10.1016\/j.josat.2026.209986_bb0215","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.18487","article-title":"Thematic analysis of state medicaid buprenorphine prior authorization requirements","volume":"6","author":"Nguemeni Tiako","year":"2023","journal-title":"JAMA Network Open"},{"issue":"9","key":"10.1016\/j.josat.2026.209986_bb0220","article-title":"Opioid agonist treatment for people who are dependent on pharmaceutical opioids","volume":"9","author":"Nielsen","year":"2022","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.josat.2026.209986_bb0225","author":"NPI Files"},{"key":"10.1016\/j.josat.2026.209986_bb0230","author":"Office of Minority Health"},{"key":"10.1016\/j.josat.2026.209986_bb0235","author":"Pardo"},{"issue":"5","key":"10.1016\/j.josat.2026.209986_bb0240","doi-asserted-by":"crossref","first-page":"720","DOI":"10.7326\/M21-4011","article-title":"The management of substance use disorders: Synopsis of the 2021 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline","volume":"175","author":"Perry","year":"2022","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1016\/j.josat.2026.209986_bb0245","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/oxfordjournals.aje.a114892","article-title":"The ecological fallacy","volume":"127","author":"Piantadosi","year":"1988","journal-title":"American Journal of Epidemiology"},{"key":"10.1016\/j.josat.2026.209986_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108317","article-title":"Adherence to buprenorphine: An analysis of prescription drug monitoring program data","volume":"216","author":"Pizzicato","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2026.209986_bb0255","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/SAR.S150253","article-title":"Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder","volume":"9","author":"Ronquest","year":"2018","journal-title":"Substance Abuse and Rehabilitation"},{"issue":"10","key":"10.1016\/j.josat.2026.209986_bb0260","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.36612","article-title":"Variation in opioid agonist dosing in clinical trials by race and ethnicity","volume":"7","author":"Ross","year":"2024","journal-title":"JAMA Network Open"},{"issue":"12","key":"10.1016\/j.josat.2026.209986_bb0265","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1111\/add.16652","article-title":"Prescribing of extended release buprenorphine injection for medicaid beneficiaries, 2018\u20132022","volume":"119","author":"Ross","year":"2024","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.josat.2026.209986_bb0270","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1080\/08897077.2021.1986882","article-title":"A bridge too far? Distance to waivered physicians and utilization of buprenorphine treatment for opioid use disorder in West Virginia Medicaid","volume":"43","author":"Saloner","year":"2022","journal-title":"Substance Abuse"},{"issue":"1 Suppl","key":"10.1016\/j.josat.2026.209986_bb0275","doi-asserted-by":"crossref","first-page":"24S","DOI":"10.1177\/0033354918793627","article-title":"A public health strategy for the opioid crisis","volume":"133","author":"Saloner","year":"2018","journal-title":"Public Health Reports"},{"issue":"9","key":"10.1016\/j.josat.2026.209986_bb0280","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.23019","article-title":"Polysubstance use among patients treated with buprenorphine from a national urine drug test database","volume":"4","author":"Saloner","year":"2021","journal-title":"JAMA Network Open"},{"issue":"1\u20132","key":"10.1016\/j.josat.2026.209986_bb0285","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.drugalcdep.2012.08.002","article-title":"Buprenorphine\/naloxone and methadone effects on laboratory indices of liver health: A randomized trial","volume":"128","author":"Saxon","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2026.209986_bb0290","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.drugpo.2019.09.003","article-title":"\u201cEverything is not right anymore\u201d: Buprenorphine experiences in an era of illicit fentanyl","volume":"74","author":"Silverstein","year":"2019","journal-title":"The International Journal on Drug Policy"},{"issue":"1","key":"10.1016\/j.josat.2026.209986_bb0295","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13722-025-00547-0","article-title":"Cross-sectional examination of characteristics of higher-dose buprenorphine prescriptions during the era of illicit fentanyl","volume":"20","author":"Stein","year":"2025","journal-title":"Addiction Science & Clinical Practice"},{"key":"10.1016\/j.josat.2026.209986_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.109889","article-title":"County-level social vulnerability and nonfatal drug overdose emergency department visits and hospitalizations, January 2018-December 2020","volume":"247","author":"Stokes","year":"2023","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1016\/j.josat.2026.209986_bb0305","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/add.70002","article-title":"The association between buprenorphine doses above 16 milligrams and treatment retention in a multi-payer national sample in the United States, 2014 to 2021","volume":"120","author":"Stringfellow","year":"2025","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/j.josat.2026.209986_bb0310","author":"SUBOXONE (buprenorphine and naloxone) sublingual tablets"},{"key":"10.1016\/j.josat.2026.209986_bb0315","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm7348a2","article-title":"Detection of illegally manufactured fentanyls and carfentanil in drug overdose deaths\u2014United States, 2021\u20132024","volume":"73","author":"Tanz","year":"2024","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"issue":"5","key":"10.1016\/j.josat.2026.209986_bb0320","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14328","article-title":"Trends in methadone dispensing for opioid use disorder after medicare payment policy changes","volume":"6","author":"Taylor","year":"2023","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2026.209986_bb0325","unstructured":"TIP 63: Medications for Opioid Use Disorder. (n.d.)."},{"issue":"8","key":"10.1016\/j.josat.2026.209986_bb0330","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.28119","article-title":"High-dose buprenorphine treatment in the setting of fentanyl","volume":"8","author":"Tsui","year":"2025","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2026.209986_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108124","article-title":"Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine","volume":"118","author":"Uscher-Pines","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"3","key":"10.1016\/j.josat.2026.209986_bb0340","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.amepre.2021.02.026","article-title":"Association between buprenorphine for opioid use disorder and mortality risk","volume":"61","author":"Vakkalanka","year":"2021","journal-title":"American Journal of Preventive Medicine"},{"issue":"6","key":"10.1016\/j.josat.2026.209986_bb0345","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/ADM.0000000000001202","article-title":"ASAM clinical considerations: Buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids","volume":"17","author":"Weimer","year":"2023","journal-title":"Journal of Addiction Medicine"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875926001062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875926001062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:29:12Z","timestamp":1783110552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875926001062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":69,"alternative-id":["S2949875926001062"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2026.209986","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends and geographic disparities in maintenance dose of buprenorphine for opioid use disorder: A cross-sectional pharmacy claims analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2026.209986","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"209986"}}